Arthrosi Therapeutics
LAGUNA HILLS, CA · Biotechnology, Healthcare, Manufacturing · 39 employees
Arthrosi Therapeutics, Inc., headquartered in San Diego, CA, is focused on developing pozdeutinurad, a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate levels, flares and tophi in patients with progressive gout. The rights to pozdeutinurad in Greater China are held by ApicHope.
Funding history
- Series series e — $153.0M — Oct 2025
- Funding Round — $60.9M — Jun 2025
- Funding Round — $7.0M — Jan 2024
- Funding Round — $15.0M — Mar 2023
- Funding Round — $26.0M — Nov 2021
Recent signals
- Oct 08, 2025: Raised $153.0M in Series series e
- Jun 24, 2025: Raised $60.9M
- Jan 26, 2024: Raised $7.0M
- Mar 03, 2023: Raised $15.0M
- Nov 15, 2021: Raised $26.0M
- Nov 15, 2021: Raised $220K
- Jun 03, 2020: Raised $8.5M
- Jan 30, 2019: Raised $11.0M
See plans & pricing → Track Arthrosi Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.